Rebeca Figueira

27 statements · 1 topic

Featured statements

▶ Ep 20 · 0:00
Fetal lung vascular remodeling predisposes fetuses with CDH to post-natal pulmonary hypertension, which plays a central role in the poor outcomes of these babies.
quote · Congenital Diaphragmatic Hernia
▶ Ep 20 · 1:20
We reported that AFSCVs promote growth and maturation in fetal hypoplastic lungs. And that these beneficial effects were exerted via the release of RNA cargo.
quote · Congenital Diaphragmatic Hernia

Nothing matches these filters — clear the search or widen the filters.

Rebeca's statements about Congenital Diaphragmatic Hernia 27 statements

Open the Congenital Diaphragmatic Hernia collection →

BOB Winner Presentation - Dr. Rebeca Figueira - EUPSA

▶ Ep 20 · 0:00
quote Fetal lung vascular remodeling predisposes fetuses with CDH to post-natal pulmonary hypertension, which plays a central role in the poor outcomes of these babies. ↗
▶ Ep 20 · 0:00
clinical Fetal lung vascular remodeling predisposes fetuses with CDH to postnatal pulmonary hypertension, which plays a central role in the poor outcomes of these babies. ↗
▶ Ep 20 · 0:30
guideline There is consensus that the prenatal period offers a window of opportunity to promote normal lung development in CDH. ↗
▶ Ep 20 · 0:30
quote There's consensus that the pre-natal period offers a window of opportunity to promote normal lung development. However, no anti-natal treatments tested to date have been successful. ↗
▶ Ep 20 · 1:00
clinical No antenatal treatments tested to date have been successful in CDH. ↗
▶ Ep 20 · 1:20
clinical AFSCVs promote growth and maturation in fetal hypoplastic lungs via the release of RNA cargo. ↗
▶ Ep 20 · 1:20
quote We reported that AFSCVs promote growth and maturation in fetal hypoplastic lungs. And that these beneficial effects were exerted via the release of RNA cargo. ↗
▶ Ep 20 · 2:00
quote But what about vascularization? The aim of this study was to investigate whether anti-natal administration of AFSCVs would also rescue fetal lung vascular development. ↗
▶ Ep 20 · 3:00
clinical EVs were isolated using ultracentrifugation and characterized in accordance with the International Society of Extracellular Vesicles guidelines. ↗
▶ Ep 20 · 3:30
clinical A nitrophen model of CDH in rats was used with antenatal AFSCV injection into the amniotic sac at E18. ↗
▶ Ep 20 · 4:30
clinical The Fulton index expresses the degree of right ventricular hypertrophy and is an indirect marker of pulmonary hypertension. ↗
▶ Ep 20 · 5:00
clinical Vascular density was rescued back to normal levels after AFSCV administration in rat CDH lungs. ↗
▶ Ep 20 · 5:30
clinical Vascular remodeling was attenuated in CDH treated lungs. ↗
▶ Ep 20 · 5:50
clinical Angiogenic factors were rescued back to normal levels after AFSCV treatment in rat lungs. ↗
▶ Ep 20 · 6:20
clinical AFSCVs attenuated the severity of right ventricular hypertrophy in CDH hearts. ↗
▶ Ep 20 · 6:50
quote But are these findings relevant to human fetal lungs? ↗
▶ Ep 20 · 8:30
clinical Vascular density was restored by AFSCV treatment in human fetal lung explants with hypoplasia. ↗
▶ Ep 20 · 9:00
clinical Vascular remodeling was attenuated in hypoplastic treated human lung explants. ↗
▶ Ep 20 · 9:20
clinical Angiogenic factors were rescued back to normal levels after AFSCV treatment in human lung explants. ↗
▶ Ep 20 · 9:50
quote After these very exciting findings, we then asked, what are the lung endothelial cell specific responses to AFSCV administration? ↗
▶ Ep 20 · 10:20
clinical Single nucleus RNA sequencing revealed a striking difference between control and CDH in the pattern and distribution of endothelial cells, which was rescued to normal distribution following AFSCV treatment. ↗
▶ Ep 20 · 11:00
clinical 245 differentially expressed genes were identified in endothelial cells. ↗
▶ Ep 20 · 11:20
clinical Genes regulating vasculogenesis and angiogenesis were downregulated in CDH lungs and upregulated in CDH treated lungs. ↗
▶ Ep 20 · 11:50
clinical AFSCV cargo contains microRNAs that control processes like angiogenesis and proliferation and migration of vascular endothelial cells. ↗
▶ Ep 20 · 12:20
clinical AFSCVs rescue vascular development and attenuate vascular remodeling in rat and human fetal hypoplastic lungs. ↗
▶ Ep 20 · 12:20
quote Therefore, anti-natal AFSCV treatment is a promising avenue to restore normal vascular development in hypoplastic lungs and potentially prevent post-natal pulmonary hypertension in babies with CDH. ↗
▶ Ep 20 · 12:40
clinical AFSCVs modulate angiogenic processes and rescue the expression of genes involved in lung vascular development. ↗